FCF Yield

The current FCF Yield of -325.0% means that bluebird bio generates negative free cash flow — the cash left after expenses and investments — equal to more than three times its market value, indicating heavy cash consumption relative to its size.

This compares poorly to the healthcare sector median of 3.4%, placing the company at the 0th percentile among sector peers, meaning almost every peer has a better (higher) FCF Yield. Trend data is not available: the year-over-year change, quarter-over-quarter change, and historical values over the last eight quarters are all listed as N/A, so no directional pattern can be assessed. The combination of a deeply negative FCF Yield and an absence of trend history implies substantial investment risk, as the company continues to burn cash at an extreme rate without a clear trajectory toward improvement. This metric directly contradicts the overall NEUTRAL verdict, as a -325% FCF Yield would typically warrant a bearish view, but the neutral stance likely accounts for other offsetting factors such as pipeline potential or cash runway.

Frequently Asked Questions

Closest Sector Peers